DHEA May Help Treat Mid-Life Depression
Posted on: Tuesday, 8 February 2005, 08:17 CST
Study suggests over-the-counter hormone can ease symptoms
HealthDay News -- Treatment with the over-the-counter hormonal therapy DHEA (dehydroepiandrosterone) may be effective in treating midlife-onset minor and major depression, according to a study in the February issue of the journal Archives of General Psychiatry.
DHEA, an androgen hormone produced naturally by the adrenal gland, is also classified as a neurosteroid due to its effects on the brain. DHEA is also sold in supplement form in stores throughout the United States.
Researchers at the U.S. National Institute of Mental Health studied 23 men and 23 women aged 45 to 65 with moderately severe midlife-onset minor or major depression. They initially received either six week of DHEA therapy or six weeks of placebo. The treatment groups were then reversed.
The study participants were evaluated at three and six weeks during the treatment phases. A 50 percent reduction on a depression rating scale was noted in 23 volunteers following DHEA treatment and in 13 volunteers after placebo.
"At present, there are no predictors of response, and with a 50 percent response rate, one would obviously select more reliable first-line treatments for this condition," the study authors said in a prepared statement.
"However, in the 50 percent of depressed outpatients who do not respond to first-line antidepressant treatment, or in those unwilling to take traditional antidepressants, DHEA may have a useful role in the treatment of mild to moderately severe midlife-onset major and minor depression," they said.
More information
U.S. National Institute of Mental Health
The American Medical Association has more about depression.
Related Articles
- New Study Demonstrates Cost Effectiveness of NeuroStar TMS Therapy(R) in the Treatment of Depression
- Unique Collaborative Alliance Prepares to Launch a Performance Improvement Initiative to Address Healthcare Gaps for Treatment-Resistant Depression
- Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
- New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
- Cyberonics Sponsors Symposium On Latest Therapeutic Strategies For Treatment- Resistant Depression (TRD) at Collegium Internationale Neuro- Psychopharmacologicum (CINP) Meeting
- Neuroimaging Research Presented at Annual American Psychiatric Association Meeting Provides New Mechanism of Action Insight for VNS Therapy in Treatment- Resistant Depression
- Leading Research Institutions Initiate Mechanism of Action Studies on Vagus Nerve Stimulation (VNS) Therapy for Treatment-Resistant Depression
- Cyberonics Sponsors Symposium on Treatment-Resistant Depression at Annual American Psychiatric Association Meeting
- Cyberonics Announces 1,100th Patient Treated With VNS Therapy(Tm) for Treatment-Resistant Depression (TRD) Since FDA Approval
- Cyberonics Clarifies Treatment-Resistant Depression (TRD) Third Party Payer Coverage Status and Plan
User Comments (0)


RSS Feeds